top of page

effectively maintains pupil dilation

and requires less use of PEDs¹⁻⁶

Reduces complications

such as IFIS, CME, and breakthrough iritis⁷⁻⁸

improveS patient experience

with less pain, greater visual acuity, and fewer to no drops¹²˒˒¹¹

OMIDRIA blocks the inflammatory cascade before it starts and leads to positive patient outcomes

Delivering an intraocular NSAID directly at the site of care

OMIDRIA, the only FDA-approved intracameral NSAID